Literature DB >> 2454811

Structure of the human chorionic gonadotropin beta-subunit fragment from pregnancy urine.

S Birken1, E G Armstrong, M A Kolks, L A Cole, G M Agosto, A Krichevsky, J L Vaitukaitis, R E Canfield.   

Abstract

A major portion of the hCG immunoreactivity detectable in pregnancy urine is derived from a fragment of hCG beta. This lacks the COOH-terminal portion of hCG beta, but retains immunoreactivity with most antibodies raised against the beta-subunit of hCG. To improve clinical measurements of hCG and assess the importance of such fragments in human urine, we have isolated and determined the structure of this molecule. The hCG beta fragment was isolated from a partially purified commercial preparation of hCG (Organon) by gel filtration and immunoaffinity chromatography using monoclonal antibodies. It was found to consist of two polypeptide chains composed of residues beta-(6-40) disulfide-bridged to residues beta-(55-92). It also differs from the beta-subunit of hCG in its carbohydrate structure, lacking sialic acid and having a low but variable amount of galactose. A beta-fragment containing the same two NH2-terminal sequences was also isolated from a single pregnant woman's urine. The two major polypeptides comprising the beta-fragment contain a total of nine half-cystine residues, raising the possibility that a free thiol may exist or that a third undetected disulfide-bridged peptide is present in the intact fragment. However, tests for the presence of a free thiol have been negative. Another intrinsic characteristic of the beta-fragment is the formation of a variable amount of dimer in solutions of neutral pH. beta-fragment will not combine with intact alpha-subunit. Despite the absence of regions beta-(1-5), beta-(41-54), and beta-(93-145), the beta fragment is recognized by the SB-6 antibody and most monoclonal antibodies elicited to the beta-subunit, thus excluding half of the amino acids of the beta-subunit from the epitope(s) where these antibodies bind.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454811     DOI: 10.1210/endo-123-1-572

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  15 in total

1.  HLH beta core fragment immunoreactivity in the urine of ovulating women: a sensitive and specific immunometric assay for its detection.

Authors:  G Kovalevskaya; S Birken; J O'Connor; J Schlatterer; Y Maydelman; R Canfield
Journal:  Endocrine       Date:  1995-12       Impact factor: 3.633

2.  Antibody recognition of a human chorionic gonadotropin epitope (hCGbeta66-80) depends on local structure retained in the free peptide.

Authors:  Craig R Gregor; Eleonora Cerasoli; James Schouten; Jascindra Ravi; Jerry Slootstra; Adrian Horgan; Glenn J Martyna; Maxim G Ryadnov; Paul Davis; Jason Crain
Journal:  J Biol Chem       Date:  2011-05-18       Impact factor: 5.157

3.  Determination of hyperglycosylated human chorionic gonadotropin produced by malignant gestational trophoblastic neoplasias and male germ cell tumors using a lectin-based immunoassay and surface plasmon resonance.

Authors:  Lisa S Kelly; Steven Birken; David Puett
Journal:  Mol Cell Endocrinol       Date:  2006-11-01       Impact factor: 4.102

4.  Patterns of LHbetacf among women in health and disease.

Authors:  Steven Birken; Ruth McChesney; Oksana Yershova; John Gaughan; Kim Pettersson; Geoff Rechenberg; Chung H Wu; George Taliadouros
Journal:  Mol Cell Endocrinol       Date:  2006-11-02       Impact factor: 4.102

Review 5.  New discoveries on the biology and detection of human chorionic gonadotropin.

Authors:  Laurence A Cole
Journal:  Reprod Biol Endocrinol       Date:  2009-01-26       Impact factor: 5.211

Review 6.  Gonadotropins in doping: pharmacological basis and detection of illicit use.

Authors:  U-H Stenman; K Hotakainen; H Alfthan
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

7.  Urinary gonadotropin fragment (UGF) measurements in the diagnosis and management of ovarian cancer.

Authors:  L A Cole; J H Nam
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug

8.  Expression of beta human chorionic gonadotrophin by non-trophoblastic non-endocrine 'normal' and malignant epithelial cells.

Authors:  R K Iles; P E Purkis; P C Whitehead; R T Oliver; I Leigh; T Chard
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

9.  Characterisation of UGP and its relationship with beta-core fragment.

Authors:  A Kardana; K D Bagshawe; B Coles; D Read; M Taylor
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

10.  The effects of beta-human chorionic gonadotrophin on the in vitro growth of bladder cancer cell lines.

Authors:  D J Gillott; R K Iles; T Chard
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.